0.506

2.70% -0.014

Pasithea Therapeutics Corp (KTTA)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$0.52

Aprire:

$0.52

Volume 24 ore:

162.61K

Relative Volume:

0.18

Capitalizzazione di mercato:

$16.91M

Reddito:

Utile/perdita netta:

$-19.73M

Rapporto P/E:

-0.2439

EPS:

-2.0742

Flusso di cassa netto:

$-16.94M

1 W Prestazione:

-1.83%

1M Prestazione:

-13.51%

6M Prestazione:

-47.84%

1 anno Prestazione:

-29.40%

Intervallo 1D:

$0.50

$0.52

Intervallo di 1 settimana:

$0.50

$0.61

Portata 52W:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Nome

Pasithea Therapeutics Corp

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

(702) 514-4174

Indirizzo

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KTTA Pasithea Therapeutics Corp	0.506	18.37M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	523.70	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.02	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	925.11	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	317.89	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.48	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie

Jul 01, 2026

Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan

Jul 01, 2026

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026

Jun 30, 2026

Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK

Jun 30, 2026

Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa

Jun 30, 2026

Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget

Jun 30, 2026

Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com

Jun 30, 2026

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network

Jun 30, 2026

Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

Jun 29, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Jun 29, 2026

Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Jun 29, 2026

Jun 28, 2026

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Jun 28, 2026

Jun 26, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan

Jun 23, 2026

Jun 22, 2026

Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks

Jun 22, 2026

Coastlands Capital LP acquires $53,000 of Pasithea stock - Investing.com UK

Jun 22, 2026

Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com - Investing.com Australia

Jun 22, 2026

Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026

Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan

Jun 22, 2026

Jun 18, 2026